Name: Peter Ludwig at NYBA 22nd Annual Meeting
Start: 2013-05-29T05:00

Why Fish

Diversity, Equity & Inclusion

Pro Bono & Social Responsibility

Legal Operations

Pricing

Legal Project Management

Knowledge Management

eDiscovery

Legal Technology Services

Trademark, Copyright & Media Litigation

Trade Secret Litigation

Appellate

Standard Essential Patents

Chancery & Corporate Governance

Post-Grant

Inter Partes Review

Post-Grant Review

Ex Parte Reexamination

Supplemental Examination

Patent

Patent Prosecution

Strategic Patent Counseling & Opinions

Patent Portfolio Management

Unitary Patent & Unified Patent Court

IP Licensing, Transactions & Agreements

Trademark & Copyright Counseling & Prosecution

Strategic Counseling, Registration & Opinions

Advertising & Marketing

Domain Names & Internet

TTAB Oppositions & Cancellations

Digital Millennium Copyright Act

Transactions & Agreements

Regulatory & Government Affairs

Communications & Spectrum Regulation

Drug & Medical Device Regulation

mHealth & Telemedicine

Privacy & Data Security

Industries

Electrical & Computer Technology

Artificial Intelligence

Digital Health

Digital Media & E-Commerce

Financial, Business & FinTech Services

Biotech & Diagnostics

Medical Devices

Pharmaceuticals

Academic Research & Medical Centers

Transportation, Aerospace & Defense

Post-Grant Annual Reports

Hosts

Name

S. Peter Ludwig

Person title

Senior Principal

Fish’s Peter Ludwig presented at the 22nd annual meeting of the NY Biotechnology Association.

NYBA 22nd Annual Meeting

Hosts

Intellectual Property Owners Association Annual Meeting 2025

Midwest IP Institute 2025

From Inspiration to Blockbuster: A MedTech Q&A

The Patent Eligibility Eras Tour: 11 Years Of Post-Alice Tumult

Analyzing SEPs: Strategies for Licensing Negotiations

Broad Prosecution History Estoppel Decision Shows Risk of Relying on Doctrine of Equivalents

IP Policy Shifts Are Promising for Patent Owners in High Tech

Navigating Change at the USPTO

John Squires Faces the Senate Judiciary Committee

Patent Diligence for VCs and PEs

Federal Circuit Clarifies Limits of Patent Eligibility for Machine Learning Claims

Can Clinical Trials Negate Patentability for Pharma Inventions?